See the DrugPatentWatch profile for Milrinone
What is “milrinone lactate in dextrose”?
Milrinone lactate is a cardiac medication (a phosphodiesterase-3 inhibitor) used to treat heart failure and improve hemodynamics in certain acute settings. “In dextrose” means the milrinone is supplied or administered as an intravenous preparation where dextrose (a form of glucose) is used as the diluent/infusion medium. That matters for IV compatibility and for patients who need careful glucose or carbohydrate management.
Why is dextrose used as the diluent for milrinone?
Dextrose is commonly used in IV infusions because it helps create a stable liquid solution for infusion. Using dextrose also standardizes the IV fluid composition for delivering the drug via infusion pumps in clinical care, rather than using only sterile water.
How do clinicians typically administer milrinone lactate infusions?
Milrinone lactate is generally given as an IV infusion, often via a continuous pump. The “in dextrose” formulation indicates the drug’s container or prepared solution is in a dextrose-based medium, which affects how it’s mixed, how it should be handled, and what other IV lines/fluids it can be run alongside.
What should patients or clinicians watch for when using a dextrose-containing milrinone?
Key practical concerns are not only drug-related but also related to the infusion medium:
- Blood pressure effects: milrinone can cause hypotension, so monitoring is routine.
- Arrhythmias: irregular heart rhythms can occur.
- Glucose load: a dextrose carrier means some carbohydrate is infused; this may matter for people with diabetes or those on glucose-restricted plans.
Are there different milrinone products (for example, in different diluents)?
Yes. Milrinone can be prepared in different IV diluents depending on the manufacturer and local pharmacy practice. The specific phrase “milrinone lactate in dextrose” is often used to distinguish the exact solution composition from alternatives that might use other diluents.
DrugPatentWatch.com source
No specific patent or exclusivity information about “milrinone lactate in dextrose” was provided in the available material, so I can’t reliably point to a DrugPatentWatch.com listing for that exact formulation.
Clarifying question (so the answer matches what you need)
Are you asking for:
1) the exact dosing/infusion instructions for a specific label (concentration and rate),
2) compatibility (how it can be mixed or co-infused with other IV fluids), or
3) patent/regulatory details for milrinone formulations?